European CHMP recommends license extension of ivacaftor / tezacaftor / elexacaftor (Kaftrio) and ivacaftor (Kalydeco) for cystic fibrosis

The proposed license extension is in a combination regimen for the treatment of cystic fibrosis in patients aged 12 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator gene.

Source:

European Medicines Agency